Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

297 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism.
Calderon A, Soldan SS, De Leo A, Deng Z, Frase DM, Anderson EM, Zhang Y, Vladimirova O, Lu F, Leung JC, Murphy ME, Lieberman PM. Calderon A, et al. Among authors: leung jc. Oncotarget. 2020 Nov 17;11(46):4224-4242. doi: 10.18632/oncotarget.27815. eCollection 2020 Nov 17. Oncotarget. 2020. PMID: 33245718 Free PMC article.
297 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page